Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only

American Journal of Medicine

Volumn 100, Issue 3, 1996, Pages 290-298

  Skinner, Martha ^a,b   Anderson, Jennifer J ^a,b   Simms, Robert ^a,b   Falk, Rodney ^a,b   Wang, Ming ^a,b   Libbey, Caryn A ^a,b   Jones, Lee Anna ^a,b   Cohen, Alan S ^a,b  

^a BOSTON MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; MELPHALAN; PARAPROTEIN; PREDNISONE;

ADULT; AMYLOIDOSIS; ARTICLE; BIOPSY; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; ORAL DRUG ADMINISTRATION; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; THROMBOCYTOPENIA;

EID: 0029939944     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)89487-9     Document Type: Article

References (29)

1. Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine. 1975; 54:271-299.
2. Isobe T, Osserman EF. Patterns of amyloidosis and their association with plasma cell dyscrasia, monoclonal immunoglobulins and Bence-Jones proteins. NEJM. 1974;290:473-477.
3. Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood. 1986;68:220-224.
4. Gertz MA, Kyle RA. Response rates and survival in primary systemic amyloidosis. Blood. 1991;77:257-262.
5. Goldfinger SE. Colchicine for familial Mediterranean fever. NEJM. 1972;287: 1302-1306.
6. Meyers S, Janowitz HD, Gumaste W, et al. Colchicine therapy of the renal amyloidosis of ulcerative colitis. Gastroenterology. 1988;94:1503-1507.
7. Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985;79:708-716.
8. Cohen AS, Rubinow A, Anderson JJ, et al. Survival of patients with primary (AL) amyloidosis and the effect of colchicine treatment: cases treated with colchicine from 1976-1983 compared with cases seen in previous years. Am J Med. 1987;82:1182-1190.
9. Gertz MA, Kyle RA. Phase II trial of alpha-tocopherol (Vitamin E) in the treatment of primary systemic amyloidosis. Am J Hematol. 1990;34:55-58.
10. Osserman EF, Sherman WH, Kyle RA. Further studies of therapy of amyloidosis with dimethylsulfoxide (DMSO). In: Glenner GG, Costa PP, Freitas AF, eds. Amyloid and Amyloidosis. Amsterdam: Exerpta Medica; 1980:563-569.
11. Gertz MA, Kyle RA. Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis. Am J Hematol. 1993;44:125-128.
12. Cohen HJ, Lessin LS, Hallal J, Burkhold P. Resolution of primary amyloidosis during chemotherapy. Ann Int Med. 1975;82:466-473.
13. Buxbaum JN, Hurley ME, Chuba J, Spiro T. Amyloidosis of the AL type. Am J Med. 1979;67:867-877.
14. Gertz MA, Kyle RA. Response of primary hepatic amyloidosis to melphalan and prednisone: a case report and review of the literature. Mayo Clinic Proc. 1986;61:218-223.
15. Schwartz RS, Cohen JR, Schrier SL. Therapy of primary amyloidosis with melphalan and prednisone. Arch Int Med. 1979;139:1144-1147.
16. Bradstock K, Clancy R, Uther J, et al. The successful treatment of primary amyloidosis with intermittant chemotherapy. Aust NZ J Med. 1978;8: 176-179.
17. Benson MD. Treatment of AL amyloidosis with melphalan, prednisone and colchicine. Arthritis Rheum. 1986;29:683-687.
18. Brown MP, Walls RS. Amyloidosis of immunoglobulin origin: useful treatment? Med J Australia. 1990;152:95-97.
19. Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978;52:818-827.
20. Zelen M. A new design for randomized clinical trials. NEJM. 1979;300:1242-1245.
21. Green MH, Harris EL, Gershenson KM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Int Med. 1986;105:360-367.
22. Gertz MA, Kyle RA. Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch Int Med. 1990;150:629-633.
23. Cox DR, Oakes D. Analysis of Survival Data. New York: Chapman and Hall; 1984.
24. Hosenpud JD, DeMarco T, Frazier OH, et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Circulation. 1991;84(suppl III):338-343.
25. Dubrey S, Falk RH. Heart transplantation in AL amyloidosis. Int J Exp Clin Invest. In press.
26. Ferrante N, Cohen AS, Anderson JJ, Skinner M. Long survival in patients with AL amyloidosis. In: Natvig JB, Forre O, Husby G, Husebekk A, Skogen B, Sletten K, Westermark P, eds. Amyloid and Amyloidosis 1990. Dordrecht, Kluwer Acad Pub; Dordrecht, the Netherlands: Kluwer Academic Publishers. 1991:813-816.
27. Marinone G, Quaglini S, Bellotti V, et al. AL amyloidosis: clinical and therapeutic aspects of an Italian study protocol. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle T, Young ID, eds. Amyloidosis. New York: Parthenon Press; 1994:206-208.
28. Comenzo RL, Simms RW, Vosburgh E, Skinner M. Advanced therapy for AL amyloidosis: IV melphalan with blood stem-cell rescue. Arthritis Rheum. 1995;38:S402.
29. van Buren M, Hene RJ, Verdonck LF, et al. Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Ann Int Med. 1995;122:508-510.